Table 1. Baseline characteristics of patients with RCC in CheckMate 214 and JAVELIN Renal 101.
| ≤60 years | >60 years | ≥75 years | ||||
|---|---|---|---|---|---|---|
| Immunotherapy | Control | Immunotherapy | Control | Immunotherapy | Control | |
| Patients, n | 435 | 448 | 529 | 514 | 77 | 78 |
| Sex | ||||||
| Male (%) | 326 (74.94) | 337 (75.22) | 383 (72.4) | 380 (73.93) | 58 (75.32) | 58 (74.36) |
| Female (%) | 109 (25.06) | 111 (24.78) | 146 (27.6) | 134 (26.07) | 19 (24.68) | 20 (25.64) |
| IMDC risk model | ||||||
| Favorable (%) | 82 (18.85) | 80 (17.86) | 113 (21.36) | 110 (21.4) | 13 (16.88) | 17 (21.79) |
| Intermediate (%) | 247 (56.78) | 265 (59.15) | 298 (56.33) | 291 (56.61) | 47 (61.04) | 46 (58.97) |
| Poor (%) | 78 (17.93) | 71 (15.85) | 83 (15.69) | 83 (16.15) | 11 (14.29) | 13 (16.67) |
| Not available (%) | 28 (6.44) | 32 (7.14) | 35 (6.62) | 30 (5.84) | 6 (7.79) | 2 (2.56) |
| MSKCC risk model | ||||||
| Favorable (%) | 91 (20.92) | 84 (18.75) | 116 (21.93) | 119 (23.15) | 13 (16.88) | 17 (21.79) |
| Intermediate (%) | 263 (60.46) | 284 (63.39) | 311 (58.79) | 313 (60.89) | 45 (58.44) | 54 (69.23) |
| Poor (%) | 51 (11.72) | 43 (9.6) | 55 (10.4) | 50 (9.73) | 11 (14.29) | 4 (5.13) |
| Not available (%) | 30 (6.9) | 37 (8.26) | 47 (8.88) | 32 (6.23) | 8 (10.39) | 3 (3.85) |
| Sarcomatoid features | ||||||
| Yes (%) | 23 (5.29) | 36 (8.04) | 22 (4.16) | 24 (4.67) | NA | 2 (2.56) |
| No (%) | 169 (38.85) | 174 (38.84) | 211 (39.89) | 199 (38.72) | 33 (42.86) | 38 (48.72) |
| Not available (%) | 243 (55.86) | 238 (53.12) | 296 (55.95) | 291 (56.61) | 44 (57.14) | 38 (48.72) |
| Tumor location | ||||||
| Primary (%) | 292 (67.13) | 301 (67.19) | 339 (64.08) | 347 (67.51) | 48 (62.34) | 47 (60.26) |
| Metastasis (%) | 92 (21.15) | 105 (23.44) | 132 (24.95) | 119 (23.15) | 19 (24.68) | 19 (24.36) |
| Not available (%) | 51 (11.72) | 42 (9.38) | 58 (10.96) | 48 (9.34) | 10 (12.99) | 12 (15.38) |
| PD-L1 expression | ||||||
| Positive (%) | 178 (40.92) | 213 (47.54) | 207 (39.13) | 206 (40.08) | 26 (33.77) | 30 (38.46) |
| Negative (%) | 215 (49.43) | 201 (44.87) | 277 (52.36) | 267 (51.95) | 40 (51.95) | 37 (47.44) |
| Not available (%) | 42 (9.66) | 34 (7.59) | 45 (8.51) | 41 (7.98) | 11 (14.29) | 11 (14.1) |
| TMB (mean±SE) | 52.01±1.51 | 48.39±1.33 | 63.07±1.41 | 63.04±1.65 | 79.16±5.43 | 62.95±2.39 |
IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; MSKCC, Memorial Sloan Kettering Cancer Center; PD-L1, programmed death-ligand 1; RCC, renal cell carcinoma; TMB, tumor mutation burden.